Management of Tachycardia and Orthostatic Intolerance in CKD Stage 3a

Initial Diagnostic Workup

• The European Society of Cardiology recommends a 12-lead ECG to rule out atrial fibrillation, structural abnormalities, or conduction defects in patients with CKD stage 3a 3
• The American Heart Association suggests transthoracic echocardiography to assess left ventricular function, left atrial size, valvular disease, and right heart function in patients with CKD stage 3a 3
• The European Society of Cardiology recommends a 24-hour Holter monitor or wearable device if paroxysmal arrhythmia is suspected despite normal resting ECG in patients with CKD stage 3a 3

Pharmacologic Management Strategy

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend initiating a cardioselective beta-blocker at the lowest dose with dose adjustments based on CKD stage in patients with CKD stage 3a 1, 2, 4
• The European Society of Cardiology suggests targeting a resting heart rate <90 bpm to reduce symptoms and complications in patients with CKD stage 3a 1, 2

Non-Pharmacologic Interventions

• The American Journal of Kidney Diseases recommends increasing fluid intake to 2-3 liters daily (unless contraindicated by volume overload) in patients with CKD stage 3a 1, 6, 7
• The European Society of Cardiology suggests increasing dietary sodium to 6-10 grams daily to expand plasma volume (monitor blood pressure) in patients with CKD stage 3a 3

CKD-Specific Considerations

• The European Heart Journal recommends avoiding digoxin unless absolutely necessary; if used, start at 0.0625 mg daily with close monitoring of renal function and drug levels in patients with CKD stage 3a 4
• The Kidney International guidelines suggest drug clearance is impaired in CKD patients—always dose-adjust medications based on eGFR in patients with CKD stage 3a 4, 3

When to Escalate Care

• The Kidney International guidelines recommend referring to cardiology if symptoms persist despite adequate rate control (<90 bpm at rest) in patients with CKD stage 3a 1, 2
• The American Journal of Kidney Diseases suggests referring to nephrology if eGFR declines to <30 mL/min/1.73 m² (CKD G4) in patients with CKD stage 3a 5